Cord blood hope for elderly blood cancer patients

NCT ID NCT07441967

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special chemotherapy combination followed by a single umbilical cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach is safe and reduces the risk of cancer returning within 180 days. Participants receive several drugs before the transplant to prepare their bodies, then are monitored for recovery and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord blood transplant plus chemotherapy (thiotepa, fludarabine, G-CSF, cytarabine, busulfan)
What this could lead to: If successful, this could offer a safer transplant option for elderly patients with blood cancers, potentially improving survival without relapse.
What could go wrong: This is a small, early-phase trial with only 44 participants. Risks include infection, graft-versus-host disease, and organ damage from the strong chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

More trials for these conditions

Other studies related to the condition(s) this trial covers.